These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 27699512)

  • 21. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
    Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
    Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
    Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine.
    Tahamtan A; Barati M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
    Iran J Immunol; 2018 Dec; 15(4):269-280. PubMed ID: 30593741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
    Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
    Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Therapeutic DNA Vaccine Targeting HPV16 E7 in Combination with Anti-PD-1/PD-L1 Enhanced Tumor Regression and Cytotoxic Immune Responses.
    Han X; Gao Z; Cheng Y; Wu S; Chen J; Zhang W
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
    Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
    Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong immune responses induced by a DNA vaccine containing HPV16 truncated E7 C-terminal linked to HSP70 gene.
    Meshkat Z; Soleimanjahi H; Mirshahabi H; Meshkat M; Kheirandish M; Hassan ZM
    Iran J Immunol; 2011 Jun; 8(2):65-75. PubMed ID: 21705833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV
    Galliverti G; Wullschleger S; Tichet M; Murugan D; Zangger N; Horton W; Korman AJ; Coussens LM; Swartz MA; Hanahan D
    Cancer Immunol Res; 2020 Jan; 8(1):131-145. PubMed ID: 31771984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer.
    Che Y; Yang Y; Suo J; An Y; Wang X
    Cancer Immunol Immunother; 2020 Dec; 69(12):2651-2664. PubMed ID: 32607768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation.
    Rahimian S; Fransen MF; Kleinovink JW; Christensen JR; Amidi M; Hennink WE; Ossendorp F
    J Control Release; 2015 Apr; 203():16-22. PubMed ID: 25660830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
    Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
    Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.